Quantitative molecular imaging of neuronal nicotinic acetylcholine receptors in the human brain with a-85380 radiotracers

Current Medical Imaging Reviews

Volumn 7, Issue 2, 2011, Pages 107-112

  Lotfipour, Shahrdad ^a   Mandelkern, Mark ^b   Brody, Arthur L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2FA; 5IA; A 85380; Human brain imaging; Nicotinic acetylcholine receptors; Positron emission tomography; Single photon emission computed tomography; Tobacco dependence; Varenicline

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; EPIBATIDINE; FLUORINE 18; IODINE 123; NICOTINIC RECEPTOR; RADIOLIGAND; TRACER;

ARTICLE; AUTORADIOGRAPHY; BRAIN; BRAIN RADIOGRAPHY; CIGARETTE SMOKING; COGNITION; GENETIC VARIABILITY; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 79955654102     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340511795445676     Document Type: Article

References (83)

1. Naqvi NH, Bechara A. The airway sensory impact of nicotine contributes to the conditioned reinforcing effects of individual puffs from cigarettes. Pharmacol Biochem Behav 2005; 81(4): 821-9.
2. Vizi ES, Lendvai B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in he central nervous system. Brain Res Brain Res Rev 1999; 30(3): 219-35.
3. Lloyd GK, Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 2000; 292(2): 461-7.
4. Role LW, Berg DK. Nicotinic receptors in the development and modulation of CNS synapses. Neuron 1996; 16(6): 1077-85.
5. Whiting PJ, Lindstrom JM. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci 1988; 8(9): 3395-404.
6. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 2001; 92(2-3): 89-108.
7. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine receptors within midbrain dopamine neurons. Neuroscience 2007; 144(4): 1347-60.
8. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382(6588): 255-7.
9. Marutle A, Warpman U, Bogdanovic N, Nordberg A. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (+/-)-[3H]epibatidine. Brain Res 1998; 801(1-2): 143-9.
10. Hellstrom-Lindahl E, Gorbounova O, Seiger A, Mousavi M, Nordberg A. Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. Brain Res Dev Brain Res 1998; 108(1-2): 147-60.
11. Pons S, Fattore L, Cossu G, et al. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 2008; 28(47): 12318-27.
12. Picciotto MR, Zoli M, Lena C, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374(6517): 65-7.
13. Ross SA, Wong JY, Clifford JJ, et al. Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci. 2000; 20(17): 6431-41.
14. Mineur YS, Picciotto MR. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol 2008; 75(1): 323-33.
15. Bailey CD, De Biasi M, Fletcher PJ, Lambe EK. The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy. J Neurosci 2010; 30(27): 9241-52.
16. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 2005; 436(7047): 103-7.
17. Hellstrom-Lindahl E, Court JA. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behav Brain Res 2000; 113(1-2): 159-68.
18. Matsuda O, Shido E, Hashikai A, et al. Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease. Psychogeriatrics 2010; 10(4): 167-72.
19. Nyback H, Halldin C, Ahlin A, Curvall M, Eriksson L. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl) 1994; 115(1-2): 31-6.
20. Muzic RF, Jr., Berridge MS, Friedland RP, Zhu N, Nelson AD. PET quantification of specific binding of carbon-11-nicotine in human brain. J Nucl Med 1998; 39(12): 2048-54.
21. Broussolle EP, Wong DF, Fanelli RJ, London ED. In vivo specific binding of [3H]1-nicotine in the mouse brain. Life Sci 1989; 44(16): 1123-32.
22. Valette H, Bottlaender M, Dolle F, Dolci L, Syrota A, Crouzel C. An attempt to visualize baboon brain nicotinic receptors with N-[11C]ABT-418 and N-[11C]methyl-cytisine. Nucl Med Commun 1997; 18(2): 164-8.
23. Fisher M, Huangfu D, Shen TY, Guyenet PG. Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent. J Pharmacol Exp Ther 1994; 270(2): 702-7.
24. Molina PE, Ding YS, Carroll FI, et al. Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nucl Med Biol 1997; 24(8): 743-7.
25. Abreo MA, Lin NH, Garvey DS, et al. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem 1996; 39(4): 817-25.
26. Koren AO, Horti AG, Mukhin AG, et al. 2-, 5-, and 6-Halo-3- (2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem 1998; 41(19): 3690-8.
27. Vaupel DB, Tella SR, Huso DL, et al. Pharmacological and toxicological evaluation of 2-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a ligand for imaging cerebral nicotinic acetylcholine receptors with positron emission tomography. J Pharmacol Exp Ther 2005; 312(1): 355-65.
28. Bottlaender M, Valette H, Roumenov D, et al. Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med 2003; 44(4): 596-601.
29. Kimes AS, Horti AG, London ED, et al. 2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. Faseb J 2003; 17(10): 1331-3.
30. Moroni M, Bermudez I. Stoichiometry and pharmacology of two human alpha4beta2 nicotinic receptor types. J Mol Neurosci 2006; 30(1-2): 95-6.
31. Liu X, Koren AO, Yee SK, Pechnick RN, Poland RE, London ED. Self-administration of 5-iodo-A-85380, a beta2-selective nicotinic receptor ligand, by operantly trained rats. Neuroreport 2003; 14(11): 1503-5.
32. Mukhin AG, Gundisch D, Horti AG, et al. 5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000; 57(3): 642-9.
33. Doll F, Dolci L, Valette H, et al. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. J Med Chem 1999; 42(12): 2251-9.
34. Valette H, Bottlaender M, Dolle F, et al. Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy] pyridine in vivo. Life Sci 1999; 64(5): PL93-7.
35. Horti AG, Scheffel U, Koren AO, et al. 2-[18F]Fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. Nucl Med Biol 1998; 25(7): 599-603.
36. Musachio JL, Scheffel U, Finley PA, et al. 5-[I-125/123]lodo- 3(2(S)-azetidinylmethoxy)pyridine, a radioiodinated analog of A-85380 for in vivo studies of central nicotinic acetylcholine receptors. Life Sci 1998; 62(22): PL351-7.
37. Vaupel DB, Mukhin AG, Kimes AS, Horti AG, Koren AO, London ED. In vivo studies with [125I]5-I-A-85380, a nicotinic acetylcholine receptor radioligand. Neuroreport 1998; 9(10): 2311-7.
38. Chefer SI, Horti AG, Lee KS, Koren AO, Jones DW, Gorey JG, et al. In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. Life Sci 1998; 63(25): PL355-60.
39. Fujita N, Shinohara M, Tanaka H, Yutani K, Nakamura H, Murase K. Quantitative mapping of cerebral deoxyhemoglobin content using MR imaging. Neuroimage 2003; 20(4): 2071-83.
40. Ogawa M, Tsukada H, Hatano K, Ouchi Y, Saji H, Magata Y. Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT). Biol Pharm Bull 2009; 32(3): 337-40.
41. Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies. Nucl Med Biol 2005; 32(8): 869-74.
42. Fujita M, Seibyl JP, Vaupel DB, et al. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging 2002; 29(2): 183-90.
43. Ueda M, Iida Y, Mukai T, et al. 5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects. Ann Nucl Med 2004; 18(4): 337-44.
44. Gallezot JD, Bottlaender M, Gregoire MC, et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18Ffluoro- A-85380 and PET. J Nucl Med 2005; 46(2): 240-7.
45. Fujita M, Ichise M, van Dyck CH, et al. Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003; 30(12): 1620-9.
46. Cosgrove KP, Mitsis EM, Bois F, et al. 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase. J Nucl Med 2007; 48(10): 1633-40.
47. Mitsis EM, Cosgrove KP, Staley JK, et al. Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT. Neurobiol Aging 2009; 30(9): 1490-7.
48. Ellis JR, Nathan PJ, Villemagne VL, et al. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380. Synapse 2009; 63(9): 752-63.
49. Czermak C, Staley JK, Kasserman S, et al. beta2 Nicotinic acetylcholine receptor availability in post-traumatic stress disorder. Int J Neuropsychopharmacol 2008; 11(3): 419-24.
50. Terriere E, Dempsey MF, Herrmann LL, et al. 5-(123)I-A-85380 binding to the alpha4beta2-nicotinic receptor in mild cognitive impairment. Neurobiol Aging 2010; 31(11): 1885-93.
51. O'Brien JT, Colloby SJ, Pakrasi S, et al. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007; 78(4): 356-62.
52. Terriere E, Sharman M, Donaghey C, et al. alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis. Neurochem Res 2008; 33(4): 643-51.
53. Ellis JR, Villemagne VL, Nathan PJ, et al. Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F] fluoro-A-85380 PET study. Neurobiol Learn Mem 2008; 90(2): 404-12.
54. Ellis JR, Nathan PJ, Villemagne VL, et al. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET. Psychopharmacology (Berl) 2009; 202(1-3): 79-91.
55. Sramek JJ, Frackiewicz EJ, Cutler NR. Review of the acetylcholinesterase inhibitor galanthamine. Expert Opin Investig Drugs 2000; 9(10): 2393-402.
56. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006; 63(8):907-15.
57. Brody AL, Mandelkern MA, Costello MR, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol 2009; 12(3): 305-16.
58. Wullner U, Gundisch D, Herzog H, et al. Smoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain. Neurosci Lett 2008; 430(1): 34-7.
59. Staley JK, Krishnan-Sarin S, Cosgrove KP, et al. Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci 2006; 26(34): 8707-14.
60. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009; 66(6): 666-76.
61. Mamede M, Ishizu K, Ueda M, et al. Temporal change in human nicotinic acetylcholine receptor after smoking cessation: 5IA SPECT study. J Nucl Med 2007; 48(11): 1829-35.
62. Mukhin AG, Kimes AS, Chefer SI, et al. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med 2008; 49(10): 1628-35.
63. Picard F, Bruel D, Servent D, et al. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain 2006; 129(Pt 8): 2047-60.
64. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48(10): 3474-7.
65. Le Foll B, Chefer SI, Kimes AS, et al. Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol Psychiatry 2009; 65(8): 714-6.
66. ACS. American Cancer Society. Cancer Facts and Figures 2007. 2007 [cited 2009 July 26]; Available from: http://www.cancer.org.
67. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. Jama 2004; 291(10): 1238-45.
68. Ananth CV, Savitz DA, Luther ER. Maternal cigarette smoking as a risk factor for placental abruption, placenta previa, and uterine bleeding in pregnancy. Am J Epidemiol 1996; 144(9): 881-9.
69. NSDUH. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings. 2008.
70. Lotfipour S, Leonard G, Perron M, et al. Orbitofrontal Cortex and Drug Use during Adolescence: Role of Prenatal Exposure to Maternal Smoking and BDNF Genotype. Archives of General Psychiatry 2009; 66(11): 1244-52.
71. Lotfipour S, Leonard G, Perron M, et al. Prenatal Exposure to Maternal Cigarette Smoking Interacts With a Polymorphism in the α6 Nicotinic Acetylcholine Receptor Gene to Influence Drug Use and Striatum Volume in Adolescence. Molecular Psychiatry. 2010; 15(1): 6-8.
72. Falk L, Nordberg A, Seiger A, Kjaeldgaard A, Hellstrom-Lindahl E. Smoking during early pregnancy affects the expression pattern of both nicotinic and muscarinic acetylcholine receptors in human first trimester brainstem and cerebellum. Neuroscience 2005; 132(2): 389-97.
73. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther 1998; 285(3): 931-45.
74. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry 2001; 40(6): 630-41.
75. Slotkin TA, Ryde IT, Seidler FJ. Separate or sequential exposure to nicotine prenatally and in adulthood: persistent effects on acetylcholine systems in rat brain regions. Brain Res Bull 2007; 74(1-3): 91-103.
76. Slotkin TA, Pinkerton KE, Auman JT, Qiao D, Seidler FJ. Perinatal exposure to environmental tobacco smoke upregulates nicotinic cholinergic receptors in monkey brain. Brain Res Dev Brain Res 2002; 133(2): 175-9.
77. Slotkin TA, Orband-Miller L, Queen KL. Development of [3H]nicotine binding sites in brain regions of rats exposed to nicotine prenatally via maternal injections or infusions. J Pharmacol Exp Ther 1987; 242(1): 232-7.
78. Slotkin TA, Seidler FJ, Qiao D, et al. Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys. Neuropsychopharmacology. 2005; 30(1): 129-44.
79. Beer A, Slotkin TA, Seidler FJ, Aldridge JE, Yanai J. Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital. Neuropsychopharmacology 2005; 30(1): 156-65.
80. Abreu-Villaca Y, Seidler FJ, Tate CA, Cousins MM, Slotkin TA. Prenatal nicotine exposure alters the response to nicotine administration in adolescence: effects on cholinergic systems during exposure and withdrawal. Neuropsychopharmacology 2004; 29(5): 879-90.
81. Hellstrom-Lindahl E, Seiger A, Kjaeldgaard A, Nordberg A. Nicotine-induced alterations in the expression of nicotinic receptors in primary cultures from human prenatal brain. Neuroscience 2001; 105(3): 527-34.
82. Pausova Z, Paus T, Abrahamowicz M, et al. Genes, maternal smoking, and the offspring brain and body during adolescence: design of the Saguenay Youth Study. Hum Brain Mapp 2007; 28(6): 502-18.
83. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47(6): 1059-66.